Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by ValuEngine

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, ValuEngine reports.

Several other equities analysts have also recently weighed in on the company. Mizuho restated a “hold” rating and issued a $4.00 price objective on shares of Abeona Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald restated a “neutral” rating on shares of Abeona Therapeutics in a report on Friday, October 18th. Royal Bank of Canada decreased their price objective on Abeona Therapeutics to $16.00 and set a “positive” rating for the company in a report on Tuesday, August 13th. They noted that the move was a valuation call. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. Finally, Maxim Group cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Abeona Therapeutics has a consensus rating of “Hold” and an average price target of $13.30.

ABEO opened at $3.41 on Tuesday. The business’s 50-day moving average price is $2.58 and its two-hundred day moving average price is $3.47. Abeona Therapeutics has a 1 year low of $1.46 and a 1 year high of $9.55. The company has a market capitalization of $172.38 million, a price-to-earnings ratio of -2.87 and a beta of 2.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.45 and a quick ratio of 2.45.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.09. Sell-side analysts anticipate that Abeona Therapeutics will post -1.55 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its holdings in shares of Abeona Therapeutics by 434.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 7,088 shares in the last quarter. Ellington Management Group LLC bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $50,000. Trexquant Investment LP bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $53,000. D. E. Shaw & Co. Inc. bought a new position in Abeona Therapeutics during the second quarter worth about $59,000. Finally, Marshall Wace LLP grew its holdings in Abeona Therapeutics by 45.9% during the second quarter. Marshall Wace LLP now owns 13,254 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 4,168 shares during the period. Institutional investors own 55.93% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: How to start trading in the forex market?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.